Cargando…

Suppression of T(H)17 Differentiation and Autoimmunity by a Synthetic ROR Ligand

T helper cells that produce Interleukin-17 (IL-17) (T(H)17 cells) are a recently identified CD4(+) T-cell subset with characterized pathological roles in autoimmune diseases(1–3). The nuclear receptors retinoic acid receptor-related orphan receptors α and γt (RORα and RORγt) have indispensible roles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solt, Laura A., Kumar, Naresh, Nuhant, Philippe, Wang, Yongjun, Lauer, Janelle L., Liu, Jin, Istrate, Monica A., Kamenecka, Theodore M., Roush, William R., Vidović, Dušica, Schürer, Stephan C., Xu, Jihong, Wagoner, Gail, Drew, Paul D., Griffin, Patrick R., Burris, Thomas P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148894/ https://www.ncbi.nlm.nih.gov/pubmed/21499262 http://dx.doi.org/10.1038/nature10075

Ejemplares similares

Regulation of p53 Stability and Apoptosis by a ROR Agonist
por: Wang, Yongjun, et al.
Publicado: (2012)

HDX-MS reveals structural determinants for RORγ hyperactivation by synthetic agonists
por: Strutzenberg, Timothy S, et al.
Publicado: (2019)

Correction: HDX-MS reveals structural determinants for RORγ hyperactivation by synthetic agonists
por: Strutzenberg, Timothy S, et al.
Publicado: (2019)

LXR-Mediated Inhibition of CD4(+) T Helper Cells
por: Solt, Laura A., et al.
Publicado: (2012)

Therapeutic Effect of a Synthetic RORα/γ Agonist in an Animal Model of Autism
por: Wang, Yongjun, et al.
Publicado: (2015)

Correction: Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression
por: Amador, Ariadna, et al.
Publicado: (2016)

Genetic and pharmacological inhibition of the nuclear receptor RORα regulates T(H)17 driven inflammatory disorders
por: Wang, Ran, et al.
Publicado: (2021)

Genetic deficiency and pharmacological modulation of RORα regulate laser-induced choroidal neovascularization
por: Liu, Chi-Hsiu, et al.
Publicado: (2023)

Regulation of Circadian Behavior and Metabolism by Synthetic REV-ERB Agonists
por: Solt, Laura A., et al.
Publicado: (2012)

Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action
por: Vidović, Dušica, et al.
Publicado: (2014)

Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation
por: Amador, Ariadna, et al.
Publicado: (2016)

Regulation of Expression of Citrate Synthase by the Retinoic Acid Receptor-Related Orphan Receptor α (RORα)
por: Crumbley, Christine, et al.
Publicado: (2012)

Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation
por: Choi, Jang Hyun, et al.
Publicado: (2011)

Pharmacological Targeting of the Mammalian Clock Regulates Sleep Architecture and Emotional Behavior
por: Banerjee, Subhashis, et al.
Publicado: (2014)

Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression
por: Amador, Ariadna, et al.
Publicado: (2016)

Metabolic Characterization of a Novel RORα Knockout Mouse Model without Ataxia
por: Billon, Cyrielle, et al.
Publicado: (2017)

The nuclear receptor REV-ERBα modulates Th17 cell-mediated autoimmune disease
por: Chang, Christina, et al.
Publicado: (2019)

Inhibition of RORα/γ suppresses atherosclerosis via inhibition of both cholesterol absorption and inflammation
por: Billon, Cyrielle, et al.
Publicado: (2016)

Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity
por: Hu, Xiao, et al.
Publicado: (2016)

The therapeutic potential of RORγ modulators in the treatment of human disease
por: Chang, Mi Ra, et al.
Publicado: (2012)

Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

ROR1 and ROR2 expression in pancreatic cancer
por: Liu, Dongli, et al.
Publicado: (2021)

Distinct functions and prognostic values of RORs in gastric cancer
por: Gu, Feng, et al.
Publicado: (2020)

RORβ modulates a gene program that is protective against articular cartilage damage
por: Chang, Mi Ra, et al.
Publicado: (2022)

Novel synthetic RORγ agonist compounds as a potential anti-tumor therapeutic approach
por: Hu, Xiao, et al.
Publicado: (2014)

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
por: Rebagay, Guilly, et al.
Publicado: (2012)

Differential Transcriptional Programming of Class-Specific B Cell Memory by T-bet and RORα
por: Wang, Nathaniel S., et al.
Publicado: (2012)

OMRT-14. Small molecule circadian clock compounds exhibit potential as a novel therapy paradigm for glioblastoma
por: Chan, Priscilla, et al.
Publicado: (2021)

Cortical RORβ is required for layer 4 transcriptional identity and barrel integrity
por: Clark, Erin A, et al.
Publicado: (2020)

RORα and RORγ expression inversely correlates with human melanoma progression
por: Brożyna, Anna A., et al.
Publicado: (2016)

RORγt and RORα signature genes in human Th17 cells
por: Castro, Glenda, et al.
Publicado: (2017)

Evolutionary Divergence in the Catalytic Activity of the CAM-1, ROR1 and ROR2 Kinase Domains
por: Bainbridge, Travis W., et al.
Publicado: (2014)

New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome
por: Raivola, Juuli, et al.
Publicado: (2022)

Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C E, et al.
Publicado: (2016)

The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards RORγ and RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1
por: John, Miya, et al.
Publicado: (2022)

ROR: Nuclear Receptor for Melatonin or Not?
por: Ma, Haozhen, et al.
Publicado: (2021)

Rorα is essential for nuocyte development
por: Wong, See Heng, et al.
Publicado: (2012)

The Th17 immune response is controlled by the Rel–RORγ–RORγT transcriptional axis
por: Ruan, Qingguo, et al.
Publicado: (2011)

Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C. E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m5l1sug9m373jeo4o817uiraas